Blog 10/27/22 Discovery of a First-In-Class MDM2 Degrader for the Treatment of Relapsed/Refractory TP-53 Wt AML & Solid Tumors 10/26/22 Development and Performance of Pharmacodynamic Assays to Demonstrate Proof-of-Mechanism for IRAK4 Degraders in a Phase1 Study 10/26/22 The Phase 1 Healthy Volunteer Clinical Trial of KT-474 10/25/22 Expression & Characterization of Novel Tissue Selective E3 Ligases 10/19/22 KT-333, A First-in-Class STAT3 Degrader, Caused Strong STAT3 Degradation and Consistent Downstream Biology In Vitro and In Vivo 8/24/22 Discovery and characterization of potent degraders of IRAK4 and IMiD substrates for oncology indications 8/16/22 MQAtlas Creates a Deep, Accurate and Global E3 Expression Atlas Enabling Targeted Protein Degradation Based Precision Medicine 7/28/22 Utilizing degraders to Modulate B & T Cell Targets for Autoimmune Diseases 6/24/22 Discovery of IRAKIMiDs: Dual-Mechanism Degraders Targeting IRAK4 and IMiDSubstrates for Oncology 6/7/22 Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications
